Organogenesis

OverviewSuggest Edit

Organogenesis Inc. is a leading regenerative medicine company with the unique skill set to take complex, living therapies from research and development, through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell-based product Apligraf®, approved for the treatment of venous leg ulcers.

TypePrivate
Founded1985
HQCanton, MA, US
Websiteorganogenesis.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Jun 2021)893(+2%)
Job Openings58
Cybersecurity ratingBMore

Key People/Management at Organogenesis

Gary S. Gillheeney

Gary S. Gillheeney

President and Chief Executive Officer, Director
Brian Grow

Brian Grow

Chief Commercial Officer
Patrick Bilbo

Patrick Bilbo

Chief Operating Officer
Antonio S. Montecalvo

Antonio S. Montecalvo

Vice President, Health Policy and Contracting
Lori Freedman

Lori Freedman

Vice President and General Counsel
Zorina Pitkin

Zorina Pitkin

Senior Vice President, Quality Systems
Show more

Organogenesis Office Locations

Organogenesis has offices in Canton, San Diego and Kanton Reinach
Canton, MA, US (HQ)
85 Dan Rd
Canton, MA, US
150 Dan Rd
San Diego, CA, US
10933 N Torrey Pines Rd, La Jolla
Kanton Reinach, CH
Christoph Merian-Ring 11
Show all (4)

Organogenesis Financials and Metrics

Summary Metrics

Founding Date

1985

Organogenesis total Funding

$75 m

Organogenesis latest funding size

$20 m

Time since last funding

4 years ago

Organogenesis investors

Organogenesis's latest funding round in May 2017 was reported to be $20 m. In total, Organogenesis has raised $75 m
Show all financial metrics

Organogenesis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Organogenesis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Organogenesis Online and Social Media Presence

Embed Graph

Organogenesis News and Updates

Thinking about trading options or stock in Ford, Organogenesis, Beyond Meat, Dollar Tree, or Plug Power?

NEW YORK, May 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, ORGO, BYND, DLTR, and PLUG. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from the sale of non-PuraPly products w…

Organogenesis Appoints Jon Giacomin to Board of Directors

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today anno…

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting

CANTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today annou…

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021

CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today an…

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance

CANTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today re…
Show more

Organogenesis Frequently Asked Questions

  • When was Organogenesis founded?

    Organogenesis was founded in 1985.

  • Who are Organogenesis key executives?

    Organogenesis's key executives are Gary S. Gillheeney, Brian Grow and Patrick Bilbo.

  • How many employees does Organogenesis have?

    Organogenesis has 893 employees.

  • Who are Organogenesis competitors?

    Competitors of Organogenesis include ACell, Biocodex and Circle Pharma.

  • Where is Organogenesis headquarters?

    Organogenesis headquarters is located at 85 Dan Rd, Canton.

  • Where are Organogenesis offices?

    Organogenesis has offices in Canton, San Diego and Kanton Reinach.

  • How many offices does Organogenesis have?

    Organogenesis has 4 offices.